ZURA

Zura Bio Limited Class A Ordinary Shares

1.41

USD

+0.17

+13.31%

Nov 10, 15:59 UTC -5

Closed

After-Market

1.39

-0.02

-1.14%

Zura Bio Limited Class A Ordinary Shares (ZURA) Earnings

ZURA Earnings Reports

Positive Surprise Ratio

ZURA beat 6 of 14 last estimates.

43%

Next Report

Date of Next Report

Mar 17, 2027

Estimate for Q4 26 (Revenue/ EPS)

-$0.19

Implied change from Q3 26 (Revenue/ EPS)

-5.00%

Implied change from Q4 25 (Revenue/ EPS)

-61.22%

Zura Bio Limited Class A Ordinary Shares earnings per share and revenue

On Oct 27, 2026, ZURA reported earnings of -0.20 USD per share (EPS) for Q3 26, beating the estimate of -0.20 USD, resulting in a 4.35% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +19.94% price change (close before vs. close after earnings).

Looking ahead to Q4 26, -- analysts forecast an EPS of -0.19 USD, with revenue projected to reach -- USD, implying an decrease of -5.00% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Kura Oncology, Inc.

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.83

Actual

-$0.78

Surprise

+7.00%

Olema Pharmaceuticals, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.63

Actual

-$0.73

Surprise

-14.53%

Autolus Therapeutics plc - ADR

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.16

Actual

-$0.21

Surprise

-27.20%

Protalix BioTherapeutics, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.03

Actual

$0.05

Surprise

+265.02%

PepGen Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.27

Actual

-$0.28

Surprise

-1.19%

Humacyte, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.09

Actual

-$0.07

Surprise

+22.91%

Seer, Inc. Class A Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.25

Actual

-$0.25

Surprise

+1.96%

Scholar Rock Holding Corporation Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.86

Actual

-$0.81

Surprise

+6.18%

TELA Bio, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.16

Actual

-$0.13

Surprise

+20.54%

Atossa Therapeutics, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.90

Actual

-$0.56

Surprise

+38.31%

FAQ

What were Zura Bio Limited Class A Ordinary Shares's earnings and revenue for the latest quarter Q3 2026?

For Q3 2026, Zura Bio Limited Class A Ordinary Shares reported EPS of -$0.20, beating estimates by 4.35%, and revenue of $0.00, 0% as expectations.

How did the market react to Zura Bio Limited Class A Ordinary Shares's Q3 2026 earnings?

The stock price moved up 19.94%, changed from $3.56 before the earnings release to $4.27 the day after.

When is Zura Bio Limited Class A Ordinary Shares expected to report next?

The next earning report is scheduled for Mar 17, 2027.

What are the forecasts for Zura Bio Limited Class A Ordinary Shares's next earnings report?

Based on -- analysts, Zura Bio Limited Class A Ordinary Shares is expected to report EPS of -$0.19 and revenue of -- for Q4 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.